title: Metabolic Imaging in Parkinson Disease.
abstract: This review focuses on recent human18F-FDG PET studies in Parkinson disease. First, an overview is given of the current analytic approaches to metabolic brain imaging data. Next, we discuss how18F-FDG PET studies have advanced understanding of the relation between distinct brain regions and associated symptoms in Parkinson disease, including cognitive decline. In addition, the value of18F-FDG PET studies in differential diagnosis, identifying prodromal patients, and the evaluation of treatment effects are reviewed. Finally, anticipated developments in the field are addressed.
authors.affiliation: Department of Neurology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands s.k.meles@umcg.nl.
authors.forename: Sanne K
authors.initials: SK
authors.lastname: Meles
authors.affiliation: Department of Neurology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
authors.forename: Laura K
authors.initials: LK
authors.lastname: Teune
authors.affiliation: Department of Neurology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
authors.forename: Bauke M
authors.initials: BM
authors.lastname: de Jong
authors.affiliation: Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; and.|Department of Nuclear Medicine, University Hospital Gent, University of Gent, Gent, Belgium.
authors.forename: Rudi A
authors.initials: RA
authors.lastname: Dierckx
authors.affiliation: Department of Neurology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
authors.forename: Klaus L
authors.initials: KL
authors.lastname: Leenders
mesh_terms: D015415:Biomarkers / Q000378:metabolism; D001921:Brain / Q000000981:diagnostic imaging / Q000378:metabolism*; D001931:Brain Mapping / Q000379:methods*; D060825:Cognitive Dysfunction / Q000175:diagnosis / Q000209:etiology / Q000378:metabolism; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics*; D005947:Glucose / Q000378:metabolism*; D006801:Humans; D007090:Image Interpretation, Computer-Assisted / Q000379:methods; D057054:Molecular Imaging; D010300:Parkinson Disease / Q000150:complications / Q000000981:diagnostic imaging* / Q000378:metabolism*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity
chemical_list: D015415:Biomarkers; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D005947:Glucose
keywords: FDG-PET; Parkinson’s disease; imaging; metabolism; networks